Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
IPHA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Innate Pharma S.A.NASDAQ: IPHA
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation outflow shrinks to €0
Q4 FY2025 stock-based compensation was €0, compared with €2.24M a year earlier. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Stock-based compensation amounted to 152.7% of revenue in FY2025, up 121.5 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
EUR · from the cash flow
- Latest · FY2025
- 4.26M EUR
- Year-over-year change
- +7.9%
- 4-year CAGR
- +12.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.26M | +7.9% |
| FY2024 | 2024-12-31 | 3.94M | -7.3% |
| FY2023 | 2023-12-31 | 4.26M | +0.2% |
| FY2022 | 2022-12-31 | 4.25M | +62.4% |
| FY2021 | 2021-12-31 | 2.62M | — |
Stock-Based Compensation vs competitors
How IPHA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.9% is the 4th highest of 8, against a peer median of -4.1%.
- Stock-based compensation amounts to 152.7% of revenue for IPHA, versus a peer median of 277.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.67M USD | -45.2% | -9.2% | 210.3% | |
| LTM Mar 2026 | $6.49M USD | -5.6% | +3.2% | — | |
| LTM Mar 2026 | $6.14M USD | +9.4% | -6.2% | 344.3% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| LTM Mar 2026 | $4.25M USD | -13.9% | -7.5% | — | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IPHA) | — | -4.1% | -4.6% | 277.3% | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| Deferred Income Tax | (1.68M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.62M | 4.25M | 4.26M | 3.94M | 4.26M |
| Change in Working Capital | (9.88M) | (12.5M) | (32.09M) | 39.16M | (10.21M) |
| Accounts Receivables | 3.39M | (4.2M) | (13.67M) | 0 | 0 |
| Inventory | (6.27M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (946K) | (7.66M) | (3.89M) | 0 | 0 |
| Other Working Capital | (6.06M) | (636K) | (10.54M) | 39.16M | (10.21M) |
| Other Non-Cash Items | (1.3M) | 1.8M | (2.24M) | (2.53M) | (630.52K) |
| Operating Cash Flow | (58.46M) | (19.15M) | (32.56M) | (6.9M) | (50.67M) |
| Capital Expenditures | (1.33M) | (1.12M) | (2.35M) | (391K) | (134.47K) |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 4.8K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 3M | 22.77M | 9.59M | 13.51M |
| Other Investing Activities | 406K | (1K) | (1.79M) | 1K | (6.38M) |
| Investing Cash Flow | (917K) | 1.88M | 20.63M | 9.2M | 7M |
| Debt Repayment | 26.63M | (2.03M) | (2.36M) | (8.94M) | (8.56M) |
| Common Stock Issued | 499K | 198K | 395K | 2.93M | 14.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187K | 198K | 395K | 2.93M | 0 |
| Financing Cash Flow | 26.82M | (1.83M) | (1.97M) | (6.01M) | 5.83M |
| Effect of Forex Changes | (483K) | (428K) | 274K | (505K) | 7.41M |
| Net Change in Cash | (33.04M) | (19.53M) | (13.62M) | (4.21M) | (30.44M) |
| Free Cash Flow | (59.79M) | (20.28M) | (34.91M) | (7.29M) | (50.81M) |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.